HER-2过表达乳腺癌患者接受TCH与TAC新辅助化疗后肿瘤恶性程度的评估

Evaluation of tumor malignancy in patients with HER-2 overexpression breast cancer after TCH and TAC neoadjuvant chemotherapy

目的:评估HER-2过表达乳腺癌患者接受TCH与TAC新辅助化疗后肿瘤恶性程度。方法:86例HER-2过表达乳腺癌患者随机分为观察组及对照组各43例,对照组接受TAC新辅助化疗,观察组接受TCH新辅助化疗,对比两组患者的肿瘤组织侵袭相关指标、自噬相关基因mRNA表达量以及治疗前后血清肿瘤标志物、血管新生分子水平的差异。结果:观察组经TCH新辅助化疗后,乳腺癌组织中侵袭促进分子OPN、CD44v6、CD10的mRNA表达量低于对照组,侵袭抑制分子TIMP-2、TIMP-3的mRNA表达量高于对照组,凋亡相关基因ATG2B、ATG4D、ATG9B、LC3-Ⅱ的mRNA表达量以及LC3-Ⅱ/LC3-I的比例显著高于对照组;治疗后1周时,观察组血清CEA、CA15-3、CA125、VEGF、bFGF水平低于对照组。结论:HER-2过表达乳腺癌患者接受TCH新辅助化疗,可显著降低肿瘤恶性程度,对远期治疗结局的优化有积极意义。

Objective：To evaluate the tumor malignancy in patients with HER-2overexpression breast cancer after TCH and TAC neoadjuvant chemotherapy.Methods：A total of 86 cases of patients with HER-2overexpression breast cancer were randomly divided into observation group and control group（n=43）,control group received TAC neoadjuvant chemotherapy,observation group received TCH neoadjuvant chemotherapy,and then the differences in mRNA expression levels of invasion-related indicators and autophagy-related genes in tumor tissue as well as the levels of serum tumor markers and angiogenesis molecules before and after treatment were compared between two groups of patients.Results：After observation group received TCH neoadjuvant chemotherapy,the mRNA expression levels of invasion-promoting molecules OPN,CD44v6 and CD10in breast cancer tissue were lower than those of control group,mRNA expression levels of invasion-inhibiting molecules TIMP-2and TIMP-3 were higher than those of control group,and mRNA expression levels of apoptosis-related genes ATG2 B,ATG4D,ATG9 Band LC3-Ⅱas well as LC3-Ⅱ/LC3-I ratio were significantly higher than those of control group;1week aftertreatment,serum CEA,CA15-3,CA125,VEGF and bFGF levels of observation group were lower than those of control group.Conclusion：TCH neoadjuvant chemotherapy can significantly reduce the tumor malignancy in patients with HER-2overexpression breast cancer,and is of positive significance in optimizing the long-term treatment outcome.